FDA
-
-
-
-
-
-
-
Biomea Fusion presents preclinical data on diabetes drug combination
-
-
-
-
-
-
-
Biomea Fusion, Inc. (BMEA) Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
-
-
-
-
-
-
-
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
-
-
-
-
-
-
-
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
-
-
-
-
-
-
-
Biomea Fusion (BMEA) Announces Clinical Hold on Trial of BMF-219 in Diabetes
-
-
-
-
-
-
-
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Associ
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

